JY
ATNM icon

Jeff Yass’s Actinium Pharmaceuticals ATNM Stock Holding History

Jeff Yass’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,500
Closed -$292K – 11923
2024
Q2 		$292K Sell
39,500
-14,400
-27% -$119K ﹤0.01% 9501
2024
Q1 		$422K Buy
53,900
+20,400
+61% +$131K ﹤0.01% 8919
2023
Q4 		$170K Buy
33,500
+3,000
+10% +$15.4K ﹤0.01% 10845
2023
Q3 		$181K Sell
30,500
-35,800
-54% -$238K ﹤0.01% 10340
2023
Q2 		$492K Sell
66,300
-1,200
-2% -$10.2K ﹤0.01% 8358
2023
Q1 		$638K Buy
67,500
+26,000
+63% +$274K ﹤0.01% 7972
2022
Q4 		$442K Buy
41,500
+16,000
+63% +$162K ﹤0.01% 8191
2022
Q3 		$188K Sell
25,500
-69,600
-73% -$433K ﹤0.01% 10933
2022
Q2 		$457K Buy
95,100
+41,100
+76% +$233K ﹤0.01% 8499
2022
Q1 		$276K Buy
54,000
+32,300
+149% +$170K ﹤0.01% 10471
2021
Q4 		$130K Sell
21,700
-39,300
-64% -$295K ﹤0.01% 11948
2021
Q3 		$540K Buy
61,000
+29,600
+94% +$206K ﹤0.01% 9177
2021
Q2 		$248K Buy
31,400
+5,800
+23% +$45.5K ﹤0.01% 11157
2021
Q1 		$195K Sell
25,600
-27,500
-52% -$234K ﹤0.01% 11443
2020
Q4 		$414K Buy
53,100
+39,200
+282% +$426K ﹤0.01% 8669
2020
Q3 		$135K Buy
+13,900
New +$153K ﹤0.01% 9753
2016
Q3 		– Sell
-543
Closed -$29K – 8367
2016
Q2 		$29K Sell
543
-620
-53% -$34.6K ﹤0.01% 8329
2016
Q1 		$69K Sell
1,163
-367
-24% -$23.2K ﹤0.01% 8578
2015
Q4 		$148K Buy
1,530
+90
+6% +$5.98K ﹤0.01% 8656
2015
Q3 		$76K Sell
1,440
-1,467
-50% -$98K ﹤0.01% 9252
2015
Q2 		$231K Buy
+2,907
New +$248K ﹤0.01% 9036

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's ATNM Position: Q2 2026 in Review

Jeff Yass reduced its Actinium Pharmaceuticals (ATNM) stake by 54% in Q2 2026, selling an estimated $77.6K and leaving 56,822 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12790.

Jeff Yass first reported a position in ATNM in Q2 2015 and has held it in 34 quarters since. The position peaked at $2.31M in Q1 2023. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Jeff Yass held 56,822 shares of Actinium Pharmaceuticals worth $55.7K as of Q2 2026.
  • Jeff Yass sold 67,176 Actinium Pharmaceuticals shares in Q2 2026, an estimated $77.6K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12790 holding.
  • Jeff Yass first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 34 quarters since.
  • Jeff Yass's Actinium Pharmaceuticals position peaked at $2.31M in Q1 2023.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.